2 Beaten-Down Healthcare Stocks That Could Soar in the Fourth Quarter

Danaher and GE Healthcare shares are down nearly 2.7% and 16.7% this year, respectively, while the S&P 500 is up 13.8%; the article argues their lower valuations leave room for a rebound if upcoming third-quarter reports reassure investors. GE Healthcare’s organic orders grew 11.1% in Q2, but margin pressure and a $26 million Patient Care Solutions segment loss remain concerns; maintaining its 3%-4% full-year organic revenue growth and $4.80-$5.00 adjusted EPS guidance could support the stock. Danaher’s Q2 biotech core revenue grew 2.5% as some bioprocessing shipments shifted to next year; management expects mid-single-digit growth in Q3 and mid- to high-single-digit growth in Q4.

Analysis

The key risk is conversion, not demand signals. At GE HealthCare, a healthy order book only supports the equity if it turns into revenue without further erosion in gross margin: pricing and productivity may lag oil, chip, and freight costs, while a PCS disposal could remove a drag but also leave stranded costs. Treat any sale as upside optionality, not as an earnings fix, until terms and retained costs are clear. At Danaher, shipment timing can flatter a quarter while masking continued customer inventory digestion; watch consumables and order conversion, not just reported segment growth. A recovery in bioprocessing would also support suppliers across the bioprocessing equipment and consumables chain, but the article does not establish the breadth of that recovery.

Over the next few weeks, earnings are binary catalysts; over 1–3 months, guidance credibility and margin delivery matter more than a single-quarter beat. Over 6–18 months, the structural question is whether bioprocessing demand reflects normalized end-market use or merely completion of destocking, and whether GEHC can restore margins without relying on asset sales. The contrarian risk: lower forward multiples may reflect lower sustainable earnings, not a bargain; estimates can reset even if headline guidance is maintained. Avoid treating the article’s optimistic framing as independently verified evidence.

Key Decisions for Investors

• GEHC: Keep exposure limited ahead of earnings; consider a staged long only if management maintains its outlook and provides evidence that margin improvement is converting into results. Reassess if guidance is cut, margin progress stalls, or PCS losses persist without a credible resolution. No price target is supportable from the supplied data.
• DHR: Prefer an earnings-confirmation entry over buying solely on the shipment-timing explanation. Require evidence of the indicated bioprocessing acceleration and stable full-year guidance; weaker consumables growth or another deferral would falsify the recovery thesis and argue against adding.
• Do not force a DHR/GEHC pair trade: their catalysts differ, and the supplied information does not establish relative valuation or earnings revisions. Track GEHC price/cost execution and DHR bioprocessing consumables and shipment conversion as separate watch items.